Saturday 17 October 2026
Export NBP’s income statement to Excel — free account
NovaBridge Biosciences
In the quarter to June 2026, EPS fell 123.3% and free cash flow grew 34.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
1.26
0.03
−2.33%
Follow NBP
NovaBridge Biosciences (NBP) P/E ratio
NovaBridge Biosciences has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ADAG Adagene Inc. Sponsored ADR compare | n/m |
| MDWD MediWound Ltd. compare | n/m |
| MSLE Satellos Bioscience Inc. compare | n/m |
| CDXS Codexis, Inc. compare | n/m |
| MOLN Molecular Partners AG Sponsored ADR compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| NBP NovaBridge Biosciences | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | 9.0× |
| MENS Jyong Biotech Ltd. compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)